MSD Israel
在场
MSD Israel 的所有者是 Merck.
是其中之一......
- Forbes Global 2000 (#162);
- Fortune 500 (#67);
- Fortune 500 Europe (#184);
- Global Fortune 500 (#229);
- Russell 3000;
- S&P 500;
- Stoxx 600;
- TOB Iconic 10,000.
Merck 是一家在股票代码 MRK (US) 下上市的公司。
Merck 在 32 个国家有直接业务。Merck 拥有 42家子公司，其中包括 EyeBio、Harpoon Therapeutics 和 Merck Animal Health。
他们在：
涉及Merck的并购和融资。
- Merck 已收购 EyeBio (公布2024七月14号).
- Merck has announced the acquisition of EyeBio (公布2024五月31号).
- Merck has announced the acquisition of Prometheus Biosciences (公布2023四月19号).
- Merck has announced the acquisition of Imago BioSciences (公布2023一月11号).
- 查看更多"Merck"相关新闻 Hide news involving Merck
高管
查看带有其 3 名主要高管的组织结构图
MSD Israel 搜索最多的简介
- Tammy Altarac, Managing Director
- Eliad Ben-Dayan, Country Medical Director
- Orly Tzalik, Business Unit Director Primary Care and Vaccines
高管在Merck变化
- Surendralal KarsanbhaiSurendralal Karsanbhai 将于20251月22作为 Director 加入公司 (新闻发布的2024十一月24号).
创建提醒
跟踪 MSD Israel 的高管变动
药店
Merck 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
MSD Israel 的最新新闻稿
- Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma - Merck.com
- Merck Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025 - Merck.com
- Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer - Merck.com
- Merck Ranks No. 1 on Newsweek’s List of America’s Most Responsible Companies 2024 - Merck.com
- Moderna and Merck Announce mRNA-4157 (V940) in Combination with KEYTRUDA® (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comple
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1) - Merck.com
- Merck to Participate in the Citi 18th Annual BioPharma Conference - Merck.com
- LYNPARZA® (olaparib)Plus Abiraterone and Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer - Merck.com
- Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com
- Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616 - Merck.com
- View more press releases Close
通过电子邮件
